BioSpace News Archive

Pharm Country

Genentech, Pfizer and Merck Identified as the Top Three Companies Driving Therapeutic Innovation in Breast Cancer

In a recent study conducted by KMK Consulting, Inc., covering Innovation & Customer Value in the Breast Cancer market, Genentech (a member of the Roche Group) was ranked as the top company delivering superior customer value and sales force engagement, as well as delivering therapeutic innovation in this space

March 9, 2020
·
3 min read
Genetown

BTL Continues to Transform Non-Invasive Aesthetics by Launching the EMSELLA® applicator with up to 2.5 Tesla (T) for the EMSCULPT® platform(1)

BTL, the manufacturer behind the revolutionary EMSCULPT technology, is continuing to set-the-pace in aesthetics and non-invasive body shaping and contouring.

March 9, 2020
·
2 min read
Biotech Bay

Blue Shield of California Becomes First Health Plan in U.S. to Cover Cost of Rapid Whole Genome Sequencing for Critically Ill Children

Innovative genetics solution pioneered by Rady Children’s Institute for Genomic Medicine; Eligible children are covered by parents’ health plan

March 9, 2020
·
4 min read
Business

ZT Corporate and Nitya Capital To Explore Joint Opportunities

Houston firms will look to collaborate on healthcare, automotive and real estate investments

March 9, 2020
·
3 min read
Biotech Beach

Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept’s Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data in the peer-reviewed Journal of Clinical Pathology that further validates the Company’s Target Selector™ qPCR Assay using “Switch Blocker” technology to identify cancer-related mutations in liquid biopsy samples

March 9, 2020
·
4 min read
Business

Refuge Biotechnologies Promotes Francesco M. Marincola, M.D., to President

Refuge Biotechnologies, Inc. (“Refuge”), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced the promotion of Francesco M. Marincola, M.D., to president.

March 9, 2020
·
2 min read
Arkin Holdings Raises $140 Million in Second Partnership Arkin Bio-Ventures II to Invest in Groundbreaking Pharma and Biotechnology Companies

Arkin Holdings, the largest and leading Israel-based life sciences investor, today announced a new partnership, Arkin Bio-Ventures II, to be funded with $140 million in capital commitments, from Arkin Holdings as well as an investor group including Migdal and Phoenix Group.

March 9, 2020
·
2 min read
FDA

NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment

NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that its RNS® System has received U.S. Food and Drug Administration (FDA) approval of MRI labeling for the RNS System, expanding treatment options for the approximately one million patients in the United States living with seizures that do not respond to medication.

March 9, 2020
·
3 min read
Business

TFF Pharmaceuticals Announces Engagement of Torreya Partners, LLC as Strategic Advisor for Partnering Efforts in China and South Korea

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Torreya Partners, LLC (Torreya) to serve as exclusive financial advisor for the Company’s partnering efforts in China and South Korea.

March 9, 2020
·
4 min read
Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment

Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236) covering ALLOCETRATM, the company’s immunotherapy candidate.

March 9, 2020
·
3 min read